menu
    • menu
    [{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"BioStata | ClinStar | LabCorp","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ BioStata | ClinStar | LabCorp","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ BioStata | ClinStar | LabCorp"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Max Neeman","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Max Neeman","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Max Neeman"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Pharmacosmos AS","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Pharmacosmos AS"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"NHS Greater Glasgow and Clyde | Pharmacosmos AS | British Heart Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ NHS Greater Glasgow and Clyde | Pharmacosmos AS | British Heart Foundation","highestDevelopmentStatusID":"11","companyTruncated":"University of Glasgow \/ NHS Greater Glasgow and Clyde | Pharmacosmos AS | British Heart Foundation"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmacosmos AS \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacosmos AS \/ Undisclosed"},{"orgOrder":0,"company":"Alberta Health services","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Oncology","graph2":"Phase III","graph3":"Alberta Health services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alberta Health services \/ Pharmacosmos AS","highestDevelopmentStatusID":"10","companyTruncated":"Alberta Health services \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Pharmacosmos AS","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Heart, Lung, and Blood Institute | Pharmacosmos AS | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Massachusetts General Hospital \/ National Heart, Lung, and Blood Institute | Pharmacosmos AS | National Institutes of Health","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ National Heart, Lung, and Blood Institute | Pharmacosmos AS | National Institutes of Health"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Pharmacosmos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baylor College of Medicine \/ Pharmacosmos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Baylor College of Medicine \/ Pharmacosmos Therapeutics"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Michael Kremke","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase IV","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacosmos AS \/ Michael Kremke","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacosmos AS \/ Michael Kremke"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"P. Noordzij","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacosmos AS \/ P. Noordzij","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ P. Noordzij"}]

    Find Clinical Drug Pipeline Developments & Deals for Ferric Derisomaltose

    Menu

    Ferric Derisomaltose

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptoma...

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            April 16, 2025

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Peking Union Medical College Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Peking Union Medical College Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Pharmacosmos AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Perioperative.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 06, 2023

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Pharmacosmos AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Zydus Lifesciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Zydus Buys Rights from Pharmacosmos to Sell Drug to Treat Anemia in India, Nepal

                            Details : MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.

                            Product Name : MonoFerric

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            September 09, 2022

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Zydus Lifesciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alberta Health services

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alberta Health services

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pharmacosmos AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Genital Neoplasms, Female.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            July 20, 2022

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pharmacosmos AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Baylor College of Medicine

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baylor College of Medicine

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Pharmacosmos Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Pharmacosmos Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Brigham and Women's Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Brigham and Women's Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Pharmacosmos AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preoperative Monoferric for Abdominal Surgery

                            Details : Monoferric (Ferric Derisomaltose) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia.

                            Product Name : Monoferric

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 28, 2022

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Pharmacosmos AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 05, 2022

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Massachusetts General Hospital

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : National Heart, Lung, and Blood Institute | Pharmacosmos AS | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Iron Deficiencies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 30, 2021

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : National Heart, Lung, and Blood Institute | Pharmacosmos AS | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : P. Noordzij

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients

                            Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 04, 2021

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : P. Noordzij

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmacosmos AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacosmos' Monoferric® (Ferric Derisomaltose) Injection is Approved by the US FDA for the Treatment of Iro...

                            Details : Monofer® is the first of the latest generation of innovative IV irons to be made available to patients in the Chinese health care system and is expected to expand the use of IV irons across multiple therapeutic areas.

                            Product Name : Monofer

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 29, 2021

                            Lead Product(s) : Ferric Derisomaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth